Menu Search
Equities

Zenith Drugs Ltd

ZENITHDRUG:NSI

Zenith Drugs Ltd

Actions
  • Price (INR)126.40
  • Today's Change-7.35 / -5.50%
  • Shares traded153.60k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Zenith Drugs Ltd grew revenues 24.95% from 916.55m to 1.15bn while net income improved 65.19% from 31.19m to 51.53m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2023, Zenith Drugs Ltd increased its cash reserves by 20.19%, or 6.06m. Cash Flow from Financing totalled 49.06m or 4.28% of revenues. In addition the company used 44.06m for operations while cash from investing totalled 1.06m.
Cash flow per share--
Price/Cash flow per share--
Book value per share13.21
Tangible book value per share13.21
More ▼

Balance sheet in INRView more

Zenith Drugs Ltd has a Debt to Total Capital ratio of 56.17%.
Current ratio1.23
Quick ratio0.8679
Total debt/total equity1.28
Total debt/total capital0.5617
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 64.70%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.